# A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients

> **NCT04161430** · PHASE3 · COMPLETED · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 766 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** DBPR108; Placebo matching sitagliptin
- **DRUG:** Placebo matching DBPR108; Sitagliptin; DBPR108
- **DRUG:** Placebo matching DBPR108; Placebo matching sitagliptin; DBPR108

## Key facts

- **NCT ID:** NCT04161430
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-02
- **Primary completion:** 2022-06-27
- **Final completion:** 2022-06-27
- **Target enrollment:** 766 (ACTUAL)
- **Last updated:** 2022-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04161430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04161430, "A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04161430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*